Abstract
The use of helium in medicine was first described by Barach who treated obstructive lesions of the airways, in 1936. Since then, only scattered reports can be found in the medical literature until the 80s, when interest in helium resurged for the treatment of acute asthma, as deaths from this disease begun to rise. At least theoretically, because of its physical properties, helium should be useful in several obstructive conditions of the airways including upper airway obstruction, croup, post-extubation stridor, asthma attacks, exacerbations of chronic obstructive pulmonary disease (COPD), etc. However, there is not enough evidence to support the systematic use of heliox to treat severe stages or acute exacerbations of COPD in either ventilated or non ventilated patients because there is currently no convincing impact on patient outcome. Therefore, at present, widespread use of heliox cannot be recommended in clinical practice.
Keywords: COPD, expiratory flow limitation, exercise, mechanical ventilation, non-invasive ventilation, helium-oxygen gas mixtures
Current Respiratory Medicine Reviews
Title: Clinical Uses of Heliox Mixtures in Chronic Obstructive Pulmonary Disease
Volume: 5 Issue: 3
Author(s): Nickolaos G. Koulouris, Antonia Koutsoukou and Edgardo D'Angelo
Affiliation:
Keywords: COPD, expiratory flow limitation, exercise, mechanical ventilation, non-invasive ventilation, helium-oxygen gas mixtures
Abstract: The use of helium in medicine was first described by Barach who treated obstructive lesions of the airways, in 1936. Since then, only scattered reports can be found in the medical literature until the 80s, when interest in helium resurged for the treatment of acute asthma, as deaths from this disease begun to rise. At least theoretically, because of its physical properties, helium should be useful in several obstructive conditions of the airways including upper airway obstruction, croup, post-extubation stridor, asthma attacks, exacerbations of chronic obstructive pulmonary disease (COPD), etc. However, there is not enough evidence to support the systematic use of heliox to treat severe stages or acute exacerbations of COPD in either ventilated or non ventilated patients because there is currently no convincing impact on patient outcome. Therefore, at present, widespread use of heliox cannot be recommended in clinical practice.
Export Options
About this article
Cite this article as:
Koulouris G. Nickolaos, Koutsoukou Antonia and D'Angelo Edgardo, Clinical Uses of Heliox Mixtures in Chronic Obstructive Pulmonary Disease, Current Respiratory Medicine Reviews 2009; 5 (3) . https://dx.doi.org/10.2174/157339809788922379
DOI https://dx.doi.org/10.2174/157339809788922379 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial [Hot Topic Advantages and Disadvantages of Inhaled Corticosteroids in the Treatment of Pulmonary Diseases Guest Editor: Nazan Cobanoglu]
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Pharmacogenomics of Asthma Beyond its Endotypes
Current Drug Metabolism Editorial from Guest Editor (Thematic Issue: The Role of Anti-Inflammatory Drugs in Respiratory Diseases)
Current Respiratory Medicine Reviews Sedation in PACU: The Role of Propofol
Current Drug Targets Meet Our Co-Editor
Drug Metabolism Letters Identification of High Affinity Bioactive Salbutamol Conformer Directed Against Mutated (Thr164Ile) Beta 2 Adrenergic Receptor
Current Topics in Medicinal Chemistry HIV-1 p24-nef DNA Vaccine Plus Protein Boost Expands T-Cell Responses in BALB/c
Current Drug Delivery Development of Vasculature Targeting Strategies for the Treatment of Chronic Inflammatory Diseases
Current Drug Targets - Inflammation & Allergy EDITORIAL (Thematic Issue): Vitamin D in Allergy and Chronic Airway Inflammation
Mini-Reviews in Medicinal Chemistry Bronchiolitis Care in the Hospital
Reviews on Recent Clinical Trials Targeting the Toll-System in Cardiovascular Sciences
Recent Patents on Inflammation & Allergy Drug Discovery Gender Differences in Metabolic Syndrome – A Key Research Issue
Endocrine, Metabolic & Immune Disorders - Drug Targets Monoclonal Antibody-based Genetic Immunotherapy
Current Gene Therapy Inhibitors for Metastasis Development
Recent Patents on Anti-Cancer Drug Discovery Fractal Analysis of the Bone Marrow in Myelodysplastic Syndromes
Current Bioinformatics Molecular Mechanisms and Treatment of Radiation-Induced Lung Fibrosis
Current Drug Targets 5'-Nucleotidases, Nucleosides and their Distribution in the Brain: Pathological and Therapeutic Implications
Current Medicinal Chemistry Mono- and Bis-2-amino-4H-pyrans: Alum Catalyzed Three- or Pseudo Five-Component Reaction of 4-Hydroxycoumarin, Malononitrile and Aldehydes
Letters in Organic Chemistry Therapeutic Modulation of Coagulation and Fibrinolysis in Acute Lung Injury and the Acute Respiratory Distress Syndrome
Current Pharmaceutical Biotechnology Nanocarriers Made from Non-Ionic Surfactants or Natural Polymers for Pulmonary Drug Delivery
Current Pharmaceutical Design